Sanchez-Infantes David, White Ursula A, Elks Carrie M, Morrison Ron F, Gimble Jeffrey M, Considine Robert V, Ferrante Anthony W, Ravussin Eric, Stephens Jacqueline M
Pennington Biomedical Research Center (D.S.-I., U.A.W., C.M.E., J.M.G., E.R., J.M.S.) and Department of Biological Sciences (J.M.S.), Louisiana State University, Baton Rouge, Louisiana 70808; Department of Nutrition (R.F.M.), UNC-Greensboro, Greensboro, North Carolina 24702; Indiana University School of Medicine (R.V.C.), Indianapolis, Indiana 46202; Department of Medicine (A.W.F.), Columbia University, New York, New York 10032; and Endocrinology Department (D.S.-I.), St Joan de Deu, 08950 Barcelona, Spain.
J Clin Endocrinol Metab. 2014 Feb;99(2):E217-25. doi: 10.1210/jc.2013-3555. Epub 2013 Dec 2.
Adipose tissue is a highly active endocrine organ that secretes many factors that affect other tissues and whole-body metabolism. Adipocytes are responsive to several glycoprotein 130 (gp130) cytokines, some of which have been targeted as potential antiobesity therapeutics.
Oncostatin M (OSM) is a gp130 family member known to inhibit adipocyte differentiation in vitro, but its effects on other adipocyte properties are not characterized. The expression of OSM in white adipose tissue (WAT) has not been evaluated in the context of obesity. Thus, our objective was to examine the expression of adipose tissue OSM in obese animals and humans.
OSM expression was examined in adipose tissues from mice with diet-induced and genetic obesity and in obese humans as well as in fractionated adipose tissue from mice. Murine adipocytes were used to examine OSM receptor expression and the effects of OSM on adipocytes, including the secretion of factors such as plasminogen activator inhibitor 1 and IL-6, which are implicated in metabolic diseases.
OSM expression is increased in rodent and human obesity/type 2 diabetes mellitus. In humans, OSM levels correlate with body weight and insulin and are inversely correlated with glucose disposal rate as measured by hyperinsulinemic-euglycemic clamp. OSM is not produced from the adipocytes in WAT but derives from cells in the stromovascular fraction, including F4/80(+) macrophages. The specific receptor of OSM, OSM receptor-β, is expressed in adipocytes and adipose tissue and increased in both rodent models of obesity examined. OSM acts on adipocytes to induce the expression and secretion of plasminogen activator inhibitor 1 and IL-6.
These data indicate that WAT macrophages are a source of OSM and that OSM levels are significantly induced in murine and human obesity/type 2 diabetes mellitus. These studies suggest that OSM produced from immune cells in WAT acts in a paracrine manner on adipocytes to promote a proinflammatory phenotype in adipose tissue.
脂肪组织是一个高度活跃的内分泌器官,可分泌许多影响其他组织和全身代谢的因子。脂肪细胞对几种糖蛋白130(gp130)细胞因子有反应,其中一些已被作为潜在的抗肥胖治疗靶点。
抑瘤素M(OSM)是gp130家族成员,已知其在体外可抑制脂肪细胞分化,但其对其他脂肪细胞特性的影响尚未明确。肥胖情况下白色脂肪组织(WAT)中OSM的表达尚未得到评估。因此,我们的目的是研究肥胖动物和人类脂肪组织中OSM的表达。
检测饮食诱导性肥胖和遗传性肥胖小鼠、肥胖人类的脂肪组织以及小鼠分离的脂肪组织中OSM的表达。使用小鼠脂肪细胞检测OSM受体表达以及OSM对脂肪细胞的影响,包括纤溶酶原激活物抑制剂1和IL-6等与代谢疾病相关因子的分泌。
啮齿动物和人类肥胖/2型糖尿病中OSM表达增加。在人类中,OSM水平与体重和胰岛素相关,与高胰岛素-正常血糖钳夹测量的葡萄糖处置率呈负相关。WAT中的脂肪细胞不产生OSM,而是来源于血管基质部分的细胞,包括F4/80(+)巨噬细胞。OSM的特异性受体OSM受体-β在脂肪细胞和脂肪组织中表达,在所检测的两种肥胖啮齿动物模型中均增加。OSM作用于脂肪细胞,诱导纤溶酶原激活物抑制剂1和IL-6的表达和分泌。
这些数据表明WAT巨噬细胞是OSM的来源,并且在小鼠和人类肥胖/2型糖尿病中OSM水平显著升高。这些研究表明,WAT中免疫细胞产生的OSM以旁分泌方式作用于脂肪细胞,促进脂肪组织中的促炎表型。